Hepatitis

Announcing its first dividend, annual revenue that doubled the prior year’s performance and a $15 billion buyback plan wasn’t enough to buoy Gilead Sciences’ shares when it dropped a bomb during its fourth-quarter earnings conference call: Discounts on the company’s hepatitis C drugs this year will be 46 percent, way more than investors and analysts […]

More than 180 million people in the world have hepatitis C, compared with the 34 million with HIV/AIDS and the roughly 30,000 who have had Ebola. Yet very little is heard about the hepatitis C virus (HCV) in the way of awareness campaigns, research funding or celebrity fundraisers. One of the global regions highly affected

‘Strong evidence of patient to patient transmission’ Five patients who were treated at the Tri-City Colonoscopy Clinic in Kitchener on Christmas Eve in 2013 were infected with hepatitis C, says Waterloo Region Public Health. The patients were among 13 who received treatment at the clinic that day, said a report published Tuesday by the public

Sharing injecting equipment is associated with a low per-event probability of hepatitis C virus (HCV) transmission, Australian investigators report in the online journal PLOS ONE. Their analysis also showed that sharing injecting equipment with someone with hepatitis C had a transmission probability of up to 6%, depending on factors such as cleaning of equipment and

As we enter 2015, nonprofit organizations that specialize in health advocacy start to compile lists of ambitious resolutions for the New Year. They pledge to spread the word more widely than ever about a particular cause, to exert influence over lawmakers, and to enlist more scientists, advocates and donors in the latest public health crusade.

BillyBob McPherson lived on Ottawa’s streets as a young teenager before “running away with the carnival.” The 55-year-old doesn’t know exactly when during his colourful life he contracted hepatitis C – he thinks it might have been in Texas in the 1980s where he had surgery and blood transfusions while working as a carny. But

Nominator: Julio Montaner is a giant in the world of HIV and AIDS research. Dr. Montaner – director of the B.C. Centre for Excellence in HIV/AIDS and past president of the International AIDS Society – pioneered the highly active anti-retroviral therapy (HAART) that has become the international standard of care. Dr. Montaner was last week

The doctor who’s been at the forefront of B.C.’s pioneering, globally imitated battle against HIV and AIDS for the past three decades is now turning his attention to another looming heath crisis – an estimated 80,000 people in B.C. infected with hepatitis C. Vancouver’s Dr. Julio Montaner was honoured last week, on the eve of

Vancouver street youth face an alarmingly high risk of hepatitis C infection because of a high incidence of injection drug use, according to a new study published in the British Medical Journal. The B.C. Centre for Excellence in HIV/AIDS tracked youth aged 14 to 26 over the course of six years. Of 940 people recruited